Abstract
Many studies have evaluated the association between cyclin D1 (CCND1) G870A polymorphism and cervical cancer susceptibility. However, these studies showed inconsistent results. The aim of this study was to derive a more precise estimation of this association. We searched PubMed and Embase for related studies that had been published in English, and ten case–control studies with a total of 2,864 cases and 3,898 controls were finally identified to be eligible studies in the meta-analysis. The association was assessed by summarizing the odds ratios (ORs) with the corresponding 95 % confidence intervals (CIs). Overall, there was no significant association between cyclin D1 (CCND1) G870A polymorphism and cervical cancer risk (for the allele model A vs. G: OR = 1.02, 95 % CI 0.88–1.19, p = 0.76; for the co-dominant model AA vs. GG: OR = 1.03, 95 % CI 0.75–1.41, p = 0.85; for the dominant model AA + GA vs. GG: OR = 1.00, 95 % CI 0.78–1.28, p = 0.99; for the recessive comparison AA vs. GA + GG: OR = 1.06, 95 % CI 0.85–1.32, p = 0.62). In subgroup analysis by ethnicity, no significant difference was found in both Asians and Caucasians. In summary, the present meta-analysis provides evidence that genotypes for the cyclin D1 (CCND1) G870A polymorphism may be not associated with genetic susceptibility of cervical cancer.
Similar content being viewed by others
References
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84. doi:10.1016/s0140-6736(11)61351-2.
On the rise globally, cancer mortality declines in u.s. Cancer discovery. 2014;4(3):Of7. doi:10.1158/2159-8290.cd-nb2014-006.
Amirian ES, Adler-Storthz K, Scheurer ME. Associations between human herpesvirus-6, human papillomavirus and cervical cancer. Cancer Lett. 2013;336(1):18–23. doi:10.1016/j.canlet.2013.04.023.
Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(10):687–97. doi:10.7326/0003-4819-155-10-201111150-00376. W214-5.
Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108.
Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.
Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.
Wang N, Qian X, Wang S, Gao H, Wang L, Huo Y, et al. CCND1 rs9344 polymorphisms are associated with the genetic susceptibility to cervical cancer in Chinese population. Mol Carcinog. 2012;51(2):196–205. doi:10.1002/mc.20801.
Ni J, Wang M, Wang M, Fu S, Zhou D, Zhang Z, et al. CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol. 2011;137(3):489–94. doi:10.1007/s00432-010-0904-x.
Catarino R, Pereira D, Breda E, Coelho A, Matos A, Lopes C, et al. Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease? Biochem Biophys Res Commun. 2008;370(1):118–22. doi:10.1016/j.bbrc.2008.03.039.
Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, et al. Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet. 2005;160(1):49–54. doi:10.1016/j.cancergencyto.2004.11.017.
Thakur N, Hussain S, Kohaar I, Tabassum R, Nasare V, Tiwari P, et al. Genetic variant of CCND1: association with HPV-mediated cervical cancer in Indian population. Biomark: Biochem Indic Expo Response Susceptibility Chem. 2009;14(4):219–25. doi:10.1080/13547500902825274.
Satinder K, Chander SR, Pushpinder K, Indu G, Veena J. Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population. Mol Cell Biochem. 2008;315(1–2):151–7. doi:10.1007/s11010-008-9799-0.
Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer J Int Du Cancer. 2009;125(8):1851–8. doi:10.1002/ijc.24529.
Warchol T, Kruszyna L, Lianeri M, Roszak A, Jagodzinski PP. Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma. Pathol Oncol Res: POR. 2011;17(1):133–7. doi:10.1007/s12253-010-9293-3.
Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan. Front Genet. 2013;4:70. doi:10.3389/fgene.2013.00070.
Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB, et al. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett. 2005;223(2):259–63. doi:10.1016/j.canlet.2004.12.024.
Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60. doi:10.1038/nrc1476.
Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10(8):772–84. doi:10.1016/s1470-2045(09)70187-1.
Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer J Int Du Cancer. 2011;129(4):920–30. doi:10.1002/ijc.25710.
Castro FA, Ivansson EL, Schmitt M, Juko-Pecirep I, Kjellberg L, Hildesheim A, et al. Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants to cervical cancer susceptibility. Int J Cancer J Int Du Cancer. 2012;130(2):349–55. doi:10.1002/ijc.26016.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
Zhou C, An H, Hu M, Liu Q, Geng P, Xu J, et al. The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2013. doi:10.1007/s13277-013-0968-8.
Zhang LQ, Wang J, Shang JQ, Bai JL, Liu FY, Guan X, et al. Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Int J Color Dis. 2011;26(10):1249–55. doi:10.1007/s00384-011-1220-x.
Wang W, Zhao Y, Yang J, Lin B, Gu H, Cao X, et al. Cyclin D1 polymorphism and oral cancer: a meta-analysis. Mol Biol Rep. 2013;40(1):87–95. doi:10.1007/s11033-012-2025-x.
Tang C, Wang Z, Yu J, Wu Y, Zhu Z, Chen N. CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis. Med Oncol (Northwood, London, England). 2011;28(4):1319–24. doi:10.1007/s12032-010-9547-7.
Sergentanis TN, Economopoulos KP. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 2011;38(8):4955–63. doi:10.1007/s11033-010-0639-4.
Li M, Dai W, Zhou H. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a meta-analysis. Sci World J. 2013;2013:689048. doi:10.1155/2013/689048.
Acknowledgments
This work was supported by the National Natural Sciences Foundation of China (No. 81272334).
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding authors
Additional information
Yongfu Wu and Hui Fu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wu, Y., Fu, H., Zhang, H. et al. Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a Meta-analysis based on Ten case–control studies. Tumor Biol. 35, 6913–6918 (2014). https://doi.org/10.1007/s13277-014-1929-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-1929-6